303- Houle SK, Padwal R, Poirier L, Tsuyuki RT. The 2014 Canadian hypertension Education pro-
gram (CHEP) guidelines for pharmacists: an update. Can Pharm J (Ott). 2014;147(4):203–8. - Kereiakes DJ, Chrysant SG, Izzo JL Jr, Littlejohn T 3rd, Melino M, Lee J, Fernandez V,
Heyrman R. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension
and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the
multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovasc Diabetol.
2012;11:134. - Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO
clinical practice guideline for the management of blood pressure in chronic kidney disease.
Kidney Int Suppl. 2012;2:337–414. - Palmer BF, Fenves AZ. Optimizing blood pressure control in patients with chronic kidney
disease. Proc (Baylor Univ Med Cent). 2010;23(3):239–45. - Ruzicka M, Quinn RR, McFarlane P, Hemmelgarn B, Ramesh Prasad GV, Feber J, Nesrallah
G, MacKinnon M, Tangri N, McCormick B, Tobe S, Blydt-Hansen TD, Hiremath S. Canadian
society of nephrology commentary on the 2012 KDIGO clinical practice guideline for the
management of blood pressure in CKD. Am J Kidney Dis. 2014;63(6):869–87. - Mann JF, Gerstein HC, Yi QL, Lonn EM, Hoogwerf BJ, Rashkow A, Yusuf S. Development of
renal disease in people at high cardiovascular risk: results of the HOPE randomized study.
J Am Soc Nephrol. 2003;14(3):641–7. - Saruta T, Hayashi K, Ogihara T, Nakao K, Fukui T, Fukiyama K, CASE-J Study Group. Effects
of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic
kidney disease: subanalysis of the CASE-J study. Hypertens Res. 2009;32(6):505–12. - Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield
JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Rydén L, Yu
CM, Teo KK, Yusuf S, TRANSCEND (Telmisartan Randomised Assessment Study in ACE
Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal
outcomes: a randomized trial. Ann Intern Med. 2009;151(1):1–10. W1-2 - Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M,
Katayama S, INNOVATION Study Group. Prevention of transition from incipient to overt
nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care.
2007;30(6):1577–8. - Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in
Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on
the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med.
2001;345(12):870–8. - Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood
pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level
meta-analysis. Ann Intern Med. 2003;139(4):244–52. - Kent DM, Jafar TH, Hayward RA, et al. Progression risk, urinary protein excretion, and treat-
ment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am
Soc Nephrol. 2007;18(6):1959–65. - Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular
Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland
I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisar-
tan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme
inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174–83. - Verbeke F, Lindley E, Van Bortel L, Vanholder R, London G, Cochat P, Wiecek A, Fouque D,
Van Biesen W. A European renal best practice (ERBP) position statement on the kidney dis-
ease: improving Global outcomes (KDIGO) clinical practice guideline for the management of
blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some
caveats for real-life application. Nephrol Dial Transplant. 2014;29(3):490–6. - Verdalles U, de Vinuesa SG, Goicoechea M, et al. Utility of bioimpedance spectroscopy (BIS)
in the management of refractory hypertension in patients with chronic kidney disease (CKD).
Nephrol Dial Transplant. 2012;27(Suppl 4):iv31–5.
18 Treatment of Hypertension in Light of the New Guidelines: Pharmacologic...